I-Mab Announces Phase 1b Dose Expansion Progress for Givastomig, Anticipates Topline Readout in Q1 2026
Reuters
Jul 17
<a href="https://laohu8.com/S/IMAB">I-Mab</a> Announces Phase 1b Dose Expansion Progress for Givastomig, Anticipates Topline Readout in Q1 2026
I-Mab, a U.S.-based global biotech company, has announced significant progress in the clinical development of its investigational therapy, givastomig. The company recently presented positive Phase 1b dose escalation data at ESMO GI 2025, which has strengthened their confidence in givastomig's potential as a best-in-class CLDN18.2-directed therapy for the treatment of gastric cancers and other applications. Following this progress, I-Mab reports faster than anticipated enrollment in the Phase 1b dose expansion cohorts. The company anticipates providing a topline readout of the study in the first quarter of 2026. This development follows I-Mab's strategic acquisition of Bridge Health, which enhances the intellectual property portfolio of givastomig by securing upstream rights and eliminating royalty obligations related to the CLDN18.2 parental antibody.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. I-Mab published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-096437), on July 17, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.